John Patrick Haran1, Gregory Hayward2, Stephen Skinner3, Chris Merritt2, David C Hoaglin4, Patricia L Hibberd5, Shan Lu6, Edward W Boyer3. 1. Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA. Electronic address: johnpharan@gmail.com. 2. Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, RI. 3. Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA. 4. Division of Biostatistics and Health Services Research, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA. 5. Department of Pediatrics and Division of Global Health, Harvard Medical School, Boston, MA. 6. Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA.
Abstract
OBJECTIVE: Antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI) are well-known outcomes from antibiotic administration. Because emergency department (ED) visits frequently result in antibiotic use, we evaluated the frequency of AAD/CDI in adults treated and discharged home with new prescriptions for antibiotics to identify risk factors for acquiring AAD/CDI. METHODS: This prospective multicenter cohort study enrolled adult patients who received antibiotics in the ED and were discharged with a new prescription for antibiotics. Antibiotic-associated diarrhea was defined as 3 or more loose stools for 2 days or more within 30 days of starting the antibiotic. C difficile infection was defined by the detection of toxin A or B within this same period. We used multivariate logistic regression to assess predictors of developing AAD. RESULTS: We enrolled and followed 247 patients; 45 (18%) developed AAD, and 2 (1%) developed CDI. Patients who received intravenous (IV) antibiotics in the ED were more likely to develop AAD/CDI than patients who did not: 25.7% (95% confidence interval [CI], 17.4-34.0) vs 12.3% (95% CI, 6.8-17.9). Intravenous antibiotics had adjusted odds ratio of 2.73 (95% CI, 1.38-5.43), and Hispanic ethnicity had adjusted odds ratio of 3.04 (95% CI, 1.40-6.58). Both patients with CDI had received IV doses of broad-spectrum antibiotics. CONCLUSION: Intravenous antibiotic therapy administered to ED patients before discharge was associated with higher rates of AAD and with 2 cases of CDI. Care should be taken when deciding to use broad-spectrum IV antibiotics to treat ED patients before discharge home.
OBJECTIVE: Antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI) are well-known outcomes from antibiotic administration. Because emergency department (ED) visits frequently result in antibiotic use, we evaluated the frequency of AAD/CDI in adults treated and discharged home with new prescriptions for antibiotics to identify risk factors for acquiring AAD/CDI. METHODS: This prospective multicenter cohort study enrolled adult patients who received antibiotics in the ED and were discharged with a new prescription for antibiotics. Antibiotic-associated diarrhea was defined as 3 or more loose stools for 2 days or more within 30 days of starting the antibiotic. C difficile infection was defined by the detection of toxin A or B within this same period. We used multivariate logistic regression to assess predictors of developing AAD. RESULTS: We enrolled and followed 247 patients; 45 (18%) developed AAD, and 2 (1%) developed CDI. Patients who received intravenous (IV) antibiotics in the ED were more likely to develop AAD/CDI than patients who did not: 25.7% (95% confidence interval [CI], 17.4-34.0) vs 12.3% (95% CI, 6.8-17.9). Intravenous antibiotics had adjusted odds ratio of 2.73 (95% CI, 1.38-5.43), and Hispanic ethnicity had adjusted odds ratio of 3.04 (95% CI, 1.40-6.58). Both patients with CDI had received IV doses of broad-spectrum antibiotics. CONCLUSION: Intravenous antibiotic therapy administered to ED patients before discharge was associated with higher rates of AAD and with 2 cases of CDI. Care should be taken when deciding to use broad-spectrum IV antibiotics to treat ED patients before discharge home.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: J Wiström; S R Norrby; E B Myhre; S Eriksson; G Granström; L Lagergren; G Englund; C E Nord; B Svenungsson Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790
Authors: Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: Kathryn A Volz; Louisa Canham; Emily Kaplan; Leon D Sanchez; Nathan I Shapiro; Shamai A Grossman Journal: Am J Emerg Med Date: 2012-11-15 Impact factor: 2.469
Authors: Arjun K Venkatesh; Benjamin P Geisler; Jennifer J Gibson Chambers; Christopher W Baugh; J Stephen Bohan; Jeremiah D Schuur Journal: PLoS One Date: 2011-09-14 Impact factor: 3.240
Authors: John P Haran; Gregory Wu; Vanni Bucci; Andrew Fischer; Edward W Boyer; Patricia L Hibberd Journal: Am J Emerg Med Date: 2015-08-21 Impact factor: 2.469
Authors: Joshua A Greenberg; Jonathan Hsu; Mohammad Bawazeer; John Marshall; Jan O Friedrich; Avery Nathens; Natalie Coburn; Gary R May; Emily Pearsall; Robin S McLeod Journal: Can J Surg Date: 2016-04 Impact factor: 2.089